The rationale is to disrupt the PD-1/PD-L1 axis, while vaccinating the patients with de DC fusion vaccine, which consists of DC fused to the patient’s myeloma, where the myeloma antigens will be presented by HLA class I to CD8+ T cells, allowing their activation and mounting a CTL response. The gene discussed is PDCD1; the disease is plasma cell myeloma.